Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aeglea BioTherapeutics stock | $8.18

Learn how to easily invest in Aeglea BioTherapeutics stock.

Aeglea BioTherapeutics Inc is a biotechnology business based in the US. Aeglea BioTherapeutics shares (AGLE) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea BioTherapeutics employs 91 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Aeglea BioTherapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AGLE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aeglea BioTherapeutics stock price (NASDAQ: AGLE)

Use our graph to track the performance of AGLE stocks over time.

Aeglea BioTherapeutics shares at a glance

Information last updated 2021-10-16.
Latest market close$8.18
52-week range$5.82 - $9.90
50-day moving average $7.62
200-day moving average $7.21
Wall St. target price$14.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.02

Buy Aeglea BioTherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aeglea BioTherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aeglea BioTherapeutics price performance over time

Historical closes compared with the close of $8.18 from 2021-10-15

1 week (2021-10-07) 4.74%
1 month (2021-09-17) 9.50%
3 months (2021-07-17) 14.73%
6 months (2021-04-16) 0.12%
1 year (2020-10-16) 0.25%
2 years (2019-10-16) 5.28%
3 years (2018-10-16) 10.02
5 years (2016-10-14) 21.19%

Aeglea BioTherapeutics financials

Revenue TTM $13.7 million
Gross profit TTM $-59,638,000
Return on assets TTM -25.72%
Return on equity TTM -48.51%
Profit margin 0%
Book value $2.43
Market capitalisation $413.1 million

TTM: trailing 12 months

Shorting Aeglea BioTherapeutics shares

There are currently 833,717 Aeglea BioTherapeutics shares held short by investors – that's known as Aeglea BioTherapeutics's "short interest". This figure is 5.9% up from 786,954 last month.

There are a few different ways that this level of interest in shorting Aeglea BioTherapeutics shares can be evaluated.

Aeglea BioTherapeutics's "short interest ratio" (SIR)

Aeglea BioTherapeutics's "short interest ratio" (SIR) is the quantity of Aeglea BioTherapeutics shares currently shorted divided by the average quantity of Aeglea BioTherapeutics shares traded daily (recently around 157008.85122411). Aeglea BioTherapeutics's SIR currently stands at 5.31. In other words for every 100,000 Aeglea BioTherapeutics shares traded daily on the market, roughly 5310 shares are currently held short.

However Aeglea BioTherapeutics's short interest can also be evaluated against the total number of Aeglea BioTherapeutics shares, or, against the total number of tradable Aeglea BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeglea BioTherapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Aeglea BioTherapeutics shares in existence, roughly 20 shares are currently held short) or 0.0255% of the tradable shares (for every 100,000 tradable Aeglea BioTherapeutics shares, roughly 26 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aeglea BioTherapeutics.

Find out more about how you can short Aeglea BioTherapeutics stock.

Aeglea BioTherapeutics share dividends

We're not expecting Aeglea BioTherapeutics to pay a dividend over the next 12 months.

Aeglea BioTherapeutics share price volatility

Over the last 12 months, Aeglea BioTherapeutics's shares have ranged in value from as little as $5.82 up to $9.9. A popular way to gauge a stock's volatility is its "beta".

AGLE.US volatility(beta: 1.59)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea BioTherapeutics's is 1.5915. This would suggest that Aeglea BioTherapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aeglea BioTherapeutics overview

Aeglea BioTherapeutics, Inc. , a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015.

Frequently asked questions

What percentage of Aeglea BioTherapeutics is owned by insiders or institutions?
Currently 1.348% of Aeglea BioTherapeutics shares are held by insiders and 92.807% by institutions.
How many people work for Aeglea BioTherapeutics?
Latest data suggests 91 work at Aeglea BioTherapeutics.
When does the fiscal year end for Aeglea BioTherapeutics?
Aeglea BioTherapeutics's fiscal year ends in December.
Where is Aeglea BioTherapeutics based?
Aeglea BioTherapeutics's address is: 805 Las Cimas Parkway, Austin, TX, United States, 78746
What is Aeglea BioTherapeutics's ISIN number?
Aeglea BioTherapeutics's international securities identification number is: US00773J1034
What is Aeglea BioTherapeutics's CUSIP number?
Aeglea BioTherapeutics's Committee on Uniform Securities Identification Procedures number is: 00773J103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site